Beraprost

An oral prostacyclin PGI2 analogue with vasodilator, antiplatelet, and cytoprotective effects, used to manage pulmonary arterial hypertension. Beraprost improves exercise capacity and symptoms in NYHA-functional class-II and -III patients with PAH and, in particular, in those with primary pulmonary hypertension.

Adverse effects
Headache, facial flushing, vasodilation.

Beraprost®

Epoprostenol A formulation of prostacyclin in trials for pulmonary vascular disease 2º to treatment with diet drugs

Mentioned in

References in periodicals archive

Sales of Beraprost sodium tablets amounted to approximately RMB112 million, an increase of approximately 12.8% as compared with the same period last year.

Sino Biopharmaceutical Announces 2019 First Quarterly Results

He had been taking clopidogrel, aspirin, and beraprost following infrarenal abdominal aortic aneurysm repair since 2013.

Spontaneous Absorption of a Lumbar Epidural Hematoma after Interlaminar Epidural Steroid Injection in a Patient with Spinal Stenosis: Close Observation as a Treatment Strategy

[PGI.sub.2] itself and several IP agonists such as beraprost and iloprost are now used to treat pulmonary arterial hypertension, chronic arterial occlusion, and other diseases in which the blood vessels are constricted and blood cannot flow to the tissues.

Prostaglandin terminal synthases as novel therapeutic targets

Beraprost and ticlopidine inhibit small aggregate formation in BRVO patients and may represent effective antiplatelet treatments [189].

New Developments in the Classification, Pathogenesis, Risk Factors, Natural History, and Treatment of Branch Retinal Vein Occlusion

As a prostacyclin analog (PGI2), beraprost sodium (BPS) avoids the above shortcomings.

The protective effect of beraprost sodium on diabetic cardiomyopathy through the inhibition of the p38 MAPK signaling pathway in high-fat-induced SD rats

For example, Beraprost, an oral prostaglandin is proving helpful in extending exercise limits (Harvey, S., 2002).

Peripheral vascular disease and the drugs used in treatment

They exceed the improvements reported for other conventional PAD drug therapies including pentoxifylline, cilostazol, dipyridamole, ticlopidine, beraprost, iloprost, naftidrofuryl, and statins, Dr.

Ramipril boosts walking times in PAD with claudication

Key words: Pulmonary arterial hypertension, prostacylin, epoprostenol, treprostonil, iloprost, beraprost

Prostanoids in the treatment of pulmonary arterial hypertension/Pulmoner arteriyel hipertansiyon tedavisinde prostanoidler

(TSE: 4503) today announced that Toray has obtained marketing approval for its oral PGI2 derivative prolonged release, Careload(R) LA Tablets 60mu/g (generic name: beraprost sodium), to be indicated for pulmonary arterial hypertension (PAH) on October 19,2007.

Toray and Astellas Pharma Announce of the Acquisition of Marketing Approval for the Pulmonary Arterial Hypertension Agent Careload(R) LA Tablets 60mu/g in Japan